Evidence map›Paper›PMID 36411481›Full record

ReviewEuropean journal of medical research2022

Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis.

Hecheng Wang, Pengpeng Wu, Deying Jiang, Hao Zhang, Jian Zhang, Yu Zong, Yanshuo Han

Open access · goldAbstract readReview
In one paragraph

Review in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Lipoprotein (a): Underrecognized Risk with a Promising Future.Reviews in cardiovascular medicine · 2024
    Review
  5. Article
  6. Impact of lipoprotein(a) and fibrinogen on prognosis in patients with coronary artery disease: A retrospective cohort study.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hecheng Wang *School of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian, China.
Pengpeng Wu *School of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian, China.
Deying JiangDepartment of Vascular Surgery, Dalian Municipal Central Hospital, Dalian, China.
Hao ZhangSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian, China.
Jian ZhangDepartment of Vascular Surgery, The First Hospital of China Medical University, Shengyang, China.
Yu ZongSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian, China.
Yanshuo HanSchool of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian, China. yanshuohan@dlut.edu.cn.ORCID https://orcid.org/0000-0002-4897-2998
Dalian University of Technology · CNDalian Municipal Central Hospital · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAt present, the relationship between serum homocysteine (Hcy), fibrinogen (FIB), lipoprotein-a (LPa), and PAD is uncertain, and there has been no meta-analysis to establish the dose-response relationship between their exposure levels and PAD. METHODS AND

resultsRelevant literature published in PubMed, Embase, and Web of Science was retrieved. The robust error meta-regression method was used to assess the linear and non-linear dose-response relationship between exposure level and PAD risk. A total of 68 articles, involving 565,209 participants, were included. Combined with continuous variables, the serum Hcy, FIB, and LPa levels of PAD patients were significantly higher than those of healthy individuals. The odds ratios (ORs) of PAD for individuals with high Hcy, FIB, and LPa levels compared with those with low levels were 1.47, 1.14, and 1.76, respectively. The study also showed that circulating Hcy, FIB, and LPa were significantly elevated in patients with PAD compared with controls. The level of Hcy and the risk of PAD presented a U-shaped distribution. The nonlinear dose-response model showed that each 1 μmol/L increase in serum Hcy increased the risk of PAD by 7%. Similarly, for each 10 mg/dL FIB and 10 mg/dL LPa increases, the risk of PAD increased by 3% and 6%, respectively.

conclusionsThis meta-analysis provided evidence that elevated Hcy, PIB, and LPa levels may increase the risk of PAD, and the risk of PAD increases with the increase in serum exposure within a certain range. By controlling Hcy level, the incidence of PAD may be reduced to control the PAD growing epidemic. TRIAL REGISTRATION NUMBER: PROSPERO (CRD42021250501), https://www.crd.york.ac.uk/prospero/.

Indexed as

HomocysteinePeripheral Arterial DiseaseFibrinogenHumansLipoprotein(a)FibrinogenHomocysteineLipoprotein(a)Dose–response meta-analysisFibrinogenHomocysteineLipoprotein(a)Peripheral arterial disease

Identifiers

PMID36411481
PMCPMC9677707
OpenAlexW4309668872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.